5‐year follow‐up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2537-2543

John Wiley & Sons Inc

Access to resources Recommend Favorite

Titration of Dosage for the Protective Effect of Zoledronic Acid on Bone Loss in Patients Submitted to Androgen Deprivation Therapy due to Prostate Cancer: A Prospective Open-Label Study

By  

Urologia Internationalis, Vol. 85, Iss. 2, 2010-07 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial

By Waltman N.   Twiss J.   Ott C.   Gross G.   Lindsey A.   Moore T.   Berg K.   Kupzyk K.  

Osteoporosis International, Vol. 21, Iss. 8, 2010-08 ,pp. : 1361-1369

Springer Publishing Company

Access to resources Recommend Favorite

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

By Karnon Jonathan  

The European Journal of Health Economics, Vol. 9, Iss. 2, 2008-05 ,pp. : 171-183

Springer Publishing Company

Access to resources Recommend Favorite

Prevention of Bone Mineral Loss by Zoledronic Acid in Men with Prostate Carcinoma Receiving Androgen Deprivation Therapy: A Prospective Randomized Trial in an Indian Population

By  

Current Urology, Vol. 2, Iss. 2, 2008-11 ,pp. : 79-86

Karger

Access to resources Recommend Favorite